Abstract
44.6 Conclusions: Several chemotherapy agents have shown minor activity in MPM. Most of the studies supporting their use as single agents or in combination are misleading because of the sample size, lack of uniform measures of response, and lack of reproducibility. However, the combination of cisplatin with pemetrexed has demonstrated improved survival in phase III studies and is now considered standard therapy for mesothelioma.
Original language | English (US) |
---|---|
Title of host publication | Tumors of the Chest |
Subtitle of host publication | Biology, Diagnosis and Management |
Publisher | Springer Berlin Heidelberg |
Pages | 515-524 |
Number of pages | 10 |
ISBN (Print) | 6293603618, 9783540310396 |
DOIs | |
State | Published - Dec 1 2006 |
ASJC Scopus subject areas
- Medicine(all)